BofA analyst Geoff Meacham lowered the firm’s price target on BioMarin to $185 from $200 and keeps a Buy rating on the shares. The firm’s estimates are “modestly above” consensus on the top-line and bottom-line for BioMarin and it expects focus on Roctavian, the analyst tells investors in an an earnings preview for the U.S. Biopharma and Biotech group.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on BMRN:
- Biotech Alert: Searches spiking for these stocks today
- ‘Hunting for Growth’: Goldman Sachs Says These 2 Stocks Could Rally up to 85% From Current Levels — Here’s Why They Have Solid Upside
- BioMarin removed from ‘US 1’ list at BofA
- Buy/Sell: Wall Street’s top 10 stock calls this week
- Netflix upgraded, Coinbase downgraded: Wall Street’s top analyst calls